Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,881 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 76,204 · Balance 216,881 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 279,181 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 62,300 · Balance 279,181 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 183,248 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 95,933 · Balance 183,248 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 256,000 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 256,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418329 · ownership.xml · nonDerivative · entry 4 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 95,933 | $38.61 | $3,703,973.13 |
DisclosureSEC source: 0001193125-26-418329 · ownership.xml · nonDerivative · entry 3 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,248 F4 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 62,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418329 · ownership.xml · nonDerivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,181 F3 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 76,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418329 · ownership.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,881 F2 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 937 | $36.69 | $34,378.53 |
DisclosureSEC source: 0001628280-26-063075 · wk-form4_1790111490.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,286 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 1,026 | $35.38 | $36,299.88 |
DisclosureSEC source: 0001628280-26-061387 · wk-form4_1789073424.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,223 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| July 07, 2026 Filed Jul 13, 2026 21:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 844 | $27.79 | $23,454.76 |
DisclosureSEC source: 0001628280-26-048054 · wk-form4_1783976614.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,249 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 937 | $26.04 | $24,399.48 |
DisclosureSEC source: 0001628280-26-044695 · wk-form4_1782161406.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,093 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 21:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 1,026 | $26.10 | $26,778.60 |
DisclosureSEC source: 0001628280-26-042286 · wk-form4_1781125288.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,030 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| April 08, 2026 Filed Apr 10, 2026 21:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 844 | $19.27 | $16,263.88 |
DisclosureSEC source: 0001628280-26-024765 · wk-form4_1775856548.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,056 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 3,749 | $19.12 | $71,680.88 |
DisclosureSEC source: 0001628280-26-020578 · wk-form4_1774300124.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,900 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 588 | $20.74 | $12,195.12 |
DisclosureSEC source: 0001628280-26-015339 · wk-form4_1772748614.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,649 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 25,525 | $22.65 | $578,141.25 |
DisclosureSEC source: 0001628280-26-012479 · wk-form4_1772146564.xml · nonDerivative · entry 3 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,237 F3 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 64,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012479 · wk-form4_1772146564.xml · nonDerivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,762 F2 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 31,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012479 · wk-form4_1772146564.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,896 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:04 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 990 | $25.59 | $25,334.10 |
DisclosureSEC source: 0001628280-26-001387 · wk-form4_1767909868.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,746 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 09, 2025 Filed Dec 17, 2025 22:26 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,033 | $25.13 | $25,959.29 |
DisclosureSEC source: 0001628280-25-057723 · wk-form4_1766010371.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,736 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 30,000 | $25.72 | $771,600.00 |
DisclosureSEC source: 0001628280-25-055636 · wk-form4_1764978247.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,769 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.53 to $25.84, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 584 | $26.74 | $15,616.16 |
DisclosureSEC source: 0001628280-25-054282 · wk-form4_1764369337.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,769 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 21:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 833 | $27.36 | $22,790.88 |
DisclosureSEC source: 0001628280-25-045019 · wk-form4_1760477454.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,353 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,032 | $26.83 | $27,688.56 |
DisclosureSEC source: 0001892616-25-000004 · wk-form4_1757970129.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,186 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 590 | $25.44 | $15,009.60 |
DisclosureSEC source: 0001628280-25-041301 · wk-form4_1756415228.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,218 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 21:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 877 | $22.27 | $19,530.79 |
DisclosureSEC source: 0001628280-25-034683 · wk-form4_1752098056.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,808 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,042 | $23.70 | $24,695.40 |
DisclosureSEC source: 0001628280-25-031101 · wk-form4_1749763452.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,685 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 583 | $22.46 | $13,094.18 |
DisclosureSEC source: 0001628280-25-028692 · wk-form4_1748642060.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,727 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 21:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 932 | $20.11 | $18,742.52 |
DisclosureSEC source: 0001628280-25-017589 · wk-form4_1744408177.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,310 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:48 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 25,687 | $22.66 | $582,067.42 |
DisclosureSEC source: 0001628280-25-016635 · wk-form4_1743716896.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,242 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 60,018 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014182 · wk-form4_1742512070.xml · nonDerivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,929 F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 38,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014182 · wk-form4_1742512070.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,911 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:25 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,151 | $25.00 | $103,775.00 |
DisclosureSEC source: 0001628280-25-012677 · wk-form4_1741901146.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,809 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 660 | $25.46 | $16,803.60 |
DisclosureSEC source: 0001628280-25-010564 · wk-form4_1741212802.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,960 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:47 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 159 | $26.54 | $4,219.86 |
DisclosureSEC source: 0001628280-25-005843 · wk-form4_1739573216.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,620 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 00:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 987 | $27.02 | $26,668.74 |
DisclosureSEC source: 0001628280-25-000982 · wk-form4_1736381417.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,779 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 26, 2024 Filed Nov 29, 2024 22:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 581 | $27.20 | $15,803.20 |
DisclosureSEC source: 0001628280-24-049480 · wk-form4_1732919407.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,766 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 23:37 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 147 | $26.19 | $3,849.93 |
DisclosureSEC source: 0001628280-24-047992 · wk-form4_1731627455.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,347 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 894 | $23.15 | $20,696.10 |
DisclosureSEC source: 0001628280-24-044811 · wk-form4_1730502079.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,494 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 611 | $25.12 | $15,348.32 |
DisclosureSEC source: 0001628280-24-040830 · wk-form4_1726695887.xml · nonDerivative · entry 3 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,388 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 21, 2024 Filed Sep 18, 2024 21:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 142 | $25.61 | $3,636.62 |
DisclosureSEC source: 0001628280-24-040830 · wk-form4_1726695887.xml · nonDerivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,999 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 11, 2024 Filed Sep 18, 2024 21:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 828 | $20.54 | $17,007.12 |
DisclosureSEC source: 0001628280-24-040830 · wk-form4_1726695887.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,141 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 29, 2024 Filed May 31, 2024 21:05 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 574 | $21.78 | $12,501.72 |
DisclosureSEC source: 0001628280-24-026081 · wk-form4_1717189506.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,969 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 17, 2024 Filed May 21, 2024 12:13 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 115 | $22.18 | $2,550.70 |
DisclosureSEC source: 0001628280-24-024447 · wk-form4_1716293596.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,543 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 18, 2024 Filed Apr 23, 2024 23:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 956 | $15.31 | $14,636.36 |
DisclosureSEC source: 0001628280-24-017495 · wk-form4_1713914040.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,658 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 21:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 520 | $17.83 | $9,271.60 |
DisclosureSEC source: 0001628280-24-012933 · wk-form4_1711400581.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,614 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-19-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,249 | $16.60 | $120,333.40 |
DisclosureSEC source: 0001628280-24-010743 · wk-form4_1710294189.xml · nonDerivative · entry 4 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,134 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 361 | $17.42 | $6,288.62 |
DisclosureSEC source: 0001628280-24-010743 · wk-form4_1710294189.xml · nonDerivative · entry 3 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,383 F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 29,206 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010743 · wk-form4_1710294189.xml · nonDerivative · entry 2 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,744 F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 41,715 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010743 · wk-form4_1710294189.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,538 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:51 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 97 | $17.35 | $1,682.95 |
DisclosureSEC source: 0001628280-24-006709 · wk-form4_1708728703.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,823 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 08-09-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 22:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,419 | $16.76 | $40,542.44 |
DisclosureSEC source: 0001628280-24-001981 · wk-form4_1706048979.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,920 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 22, 2023 Filed Dec 28, 2023 21:46 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 314 | $16.79 | $5,272.06 |
DisclosureSEC source: 0001628280-23-042810 · wk-form4_1703800002.xml · nonDerivative · entry 1 Wichterman Troy · CIK 0001892616 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,339 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 06-19-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.